Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
This study demonstrates that treatment with olipudase alfa for 30 months is well-tolerated and associated with life-transforming sustained improvem ents in relevant disease clinical measures.
Source: Journal of Inherited Metabolic Disease - Category: Internal Medicine Source Type: research
More News: Back Pain | Headache | Hematology | Internal Medicine | Liver | Migraine | Pain | Statistics | Study | Urology & Nephrology